HUGE NEWS!!!!!
Thursday, March 08 2012 2:00 PM, EST OMNIlife science, Inc. Announces FDA Clearance of the Apex Revision Knee System PR Web "Press Releases"
East Taunton, MA (PRWEB) March 08, 2012
OMNIlife science, Inc. (a subsidiary of Orthopaedic Synergy, Inc. ) today announced clearance of its Apex Revision Knee System by the United States Food and Drug Administration . The Apex Knee System, including the new Apex Revision Knee, is intended for use as a primary or revision total knee replacement. This implant system may be used for conditions such as non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis. Combined with an intuitive surgical protocol and instrumentation, Apex Knee prostheses are designed to provide surgeons intra-operative versatility, allowing them to effectively provide patients with restored range of motion and pain relief.
The Apex Revision Knee is intended for patients that require additional stabilization due to inadequate ligament function and may require augmentation and/or stem extensions due to inadequate bone stock; conditions which may affect more than 70,000 knee replacement patients a year in the U.S. The Revision Knee System adds new revision femoral components, constrained tibial inserts, femoral augments, and stems to the current Apex Knee System. The Apex Revision Knee shares the foundation of the Apex Knee Systems kinematics, sizing, and versatility allowing surgeons to provide a continuum of care for their patients requiring total knee replacement.
The addition of the Apex Revision Knee System is an important step in our strategy to offer a complete total knee replacement product line to our customers. The Apex Knee system, including primary cruciate retaining, posterior stabilized and revision knee options, offers the key features that surgeons are looking for in a contemporary total knee replacement system. said George Cipolletti , Chief Executive Officer of OMNIlife science, Inc.
About OMNIlife science, Inc. OMNIlife science, Inc. was founded in 1999 as an organization committed to the design, manufacture and distribution of high quality orthopaedic devices. Our corporate headquarters are located in East Taunton, Massachusetts . Our products are prescribed by orthopaedic surgeons for their patients who require total joint replacement. OMNI is ISO 13485 certified and its products are FDA cleared and CE approved. OMNI is emerging as a leader in modular hip stem technology and total knee replacement systems. We continue to challenge the design and functionality of our products based on continued advances in reconstructive surgical techniques, anatomic and biomechanical data, as well as input from surgeons. Our corporate strategic objectives include continued growth through line extensions to our hip and knee product offerings as well as the introduction of new products that will complement our current product portfolio and allow us to provide new clinical options for our customers. Additional information can be found at http://www.omnils.com.
About Orthopaedic Synergy, Inc. Orthopaedic Synergy, Inc. functions as a holding company for OMNIlife science, Inc., Enztec Limited and PRAXIM, SA . Together these companies represent a global reconstructive orthopaedic concern that is committed to the design, manufacture and distribution of high quality orthopaedic devices. Company objectives include continued growth through strategic acquisition of organizations with complementary technology. The goal is to acquire firms that enhance the development of line extensions to our companys current product offerings as well as innovative new products that provide improved clinical options for our customers. Additional information can be found at http://www.orthopedicsynergy.com.
Read the full story at http://www.prweb.com/releases/2012/3/prweb9263558.htm
News 
Market Data 
Discover 
AI
